

Murray Motion For Reporting Calendar Year 2013

Pursuant to the Senate Order on departmental and agency contracts the following table sets out contracts entered into by Cancer Australia which provide for a consideration to the value of \$100,000 or more and which (a) have not been

Note 1: Most of the contracts listed contain confidentiality provisions of a general nature that are designed to protect the confidential information of the parties that may be obtained or generated in carrying out the contract. Reasons for

Note 2: Columns (f) and (g) relate to specific contract schedules or clauses that have been inserted into the standard form contract that require the parties to maintain confidentiality of any of its provisions.

(a)	(b)	(c)	(d)	(e)	(f)	(g)	(h)	(i)		
Contractor	Subject Matter	Amount of Consideration \$	Start Date	Anticipated End Date	Whether contract contains provisions requiring the parties to maintain confidentiality of any of its provisions (Y/N)	Reason(s)	Whether contract contains other requirements of confidentiality (Y/N)	Reason(s)	Agency Ref	Contract / Grant
AOT Hotels	Provide accommodation booking system to Cancer Australia as part of the Phase 2 implementation.	132,000.00	01/07/13	30/06/15	N		N		CA-13-14/01 - D	C
CBRE Australia	Lease for Level 14 300 Elizabeth St, Surry Hills NSW 2010	3,292,893.13	01/10/11	28/02/15	N		N		CA-D11-12/31	C
Chill IT	IT Maintenance and Support	699,339.30	01/07/12	01/06/15	N		N		CA-12-13/21 - D	C
Monash Health	Procurement of evaluation data	120,000.00	24/06/13	30/06/15	N		N		CA-1314/20-D	C
Monash University	Investigating symptoms of lung cancer - a guide for general practitioners	941,620.00	01/02/11	31/12/16	N		N		CA-A1011/02	C
NGA.NET Pty Ltd	Implement and support a E-Recruit system for Cancer Australia	163,812.00	21/06/13	20/06/16	N		N		CA-1314/07-D	C
NHMRC Clinical Trials Centre	Technical Services of a Genomic Cancer Clinical Trial Initiative (GCCTI) to develop mutation-specific cancer clinical trials protocols	1,350,000.00	25/06/13	01/08/16	N		N		CA-A1213/86	C
Queen Elizabeth Hospital	Procurement of evaluation data	120,000.00	27/06/13	30/06/15	N		N		CA-1314/22-D	C
Roex Management	Chair services for CA Audit Committee	176,000.00	27/09/07	27/09/14	N		N		CA-D /0708/03/V2	C
Telstra	Provision of 2 NCS links (Canberra and Melbourne office) for internet services.	102,584.86	19/02/12	18/02/14	N		N		CA-D12-13/15	C
Telstra	For Rural Women Project	265,200.00	20/05/11	29/07/14	N		N		CA-D 11-12/10	C

(a)	(b)	(c)	(d)	(e)	(f)	(g)	(h)	(i)		
Contractor	Subject Matter	Amount of Consideration \$	Start Date	Anticipated End Date	Whether contract contains provisions requiring the parties to maintain confidentiality of any of its provisions (Y/N)	Reason(s)	Whether contract contains other requirements of confidentiality (Y/N)	Reason(s)	Agency Ref	Contract / Grant
University of Sydney	Technical services of a quality-of-life office to the 13 trials groups supported under the Support for Cancer Clinical Trials program	750,000.00	25/06/13	01/08/16	N		N		CA-A1213/87	C
University of Sydney	Cancer Learning Website Redevelopment	200,000.00	11/12/13	30/06/14	N		N		CA-1314/42-D	C
University of Technology, Sydney	Technical services of health-economics and pharmaco-economics to the 13 trials groups supported under the Support for Cancer Clinical Trials program	898,896.00	25/06/13	01/08/16	N		N		CA-A1213/85	C
Australasian Gastro-Intestinal Trials Group (AGITG) through University of Sydney	Support for Cancer Clinical Trials - AGITG	1,380,000.00	25/06/13	31/08/16	N		N		CA-A1213/80	G
Australasian Leukaemia and Lymphoma Group (ALLG)	Support for Cancer Clinical Trials - ALLG	1,518,000.00	25/06/13	31/08/16	N		N		CA-A1213/82	G
Australasian Lung Cancer Trials Group (ALTG) through University of Sydney	Support for Cancer Clinical Trials - ALTG	1,380,000.00	25/06/13	31/08/16	N		N		CA-A1213/73	G
Australasian Sarcoma Study Group (ASSG) through University of Melbourne	Support for Cancer Clinical Trials - ASSG	1,379,998.00	25/06/13	31/08/16	N		N		CA-A1213/74	G
Australia and New Zealand Breast Cancer Trials Group (ANZBCTG) through Newcastle Innovation Ltd	Support for Cancer Clinical Trials - ANZBCTG	1,517,938.00	26/06/13	31/08/16	N		N		CA-A1213/77	G
Australia and New Zealand Melanoma Trials Group (ANZMTG) through University of Sydney	Support for Cancer Clinical Trials - ANZMTG	1,380,000.00	25/06/13	31/08/16	N		N		CA-A1213/83	G

(a)	(b)	(c)	(d)	(e)	(f)	(g)	(h)	(i)		
Contractor	Subject Matter	Amount of Consideration \$	Start Date	Anticipated End Date	Whether contract contains provisions requiring the parties to maintain confidentiality of any of its provisions (Y/N)	Reason(s)	Whether contract contains other requirements of confidentiality (Y/N)	Reason(s)	Agency Ref	Contract / Grant
Australia New Zealand Gynaecological Oncology Group (ANZGOG) through University of Sydney	Support for Cancer Clinical Trials - ANZGOG	1,380,000.00	25/06/13	31/08/16	N		N		CA-A1213/79	G
Australian and New Zealand Children's Haematology/Oncology Group (ANZCHOG) through Monash University	Support for Cancer Clinical Trials - ANZCHOG	1,379,173.00	25/06/13	31/08/16	N		N		CA-A1213/81	G
Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) through University of Sydney	Support for Cancer Clinical Trials - ANZUP	1,380,000.00	25/06/13	31/08/16	N		N		CA-A1213/78	G
Australian National University	2010 Priority Driven Collaborative Cancer Research Scheme (PDCCRS): Targeting of two Aspects of Metabolism (TOTAM) for cancer therapy	546,165.40	16/02/11	31/05/14	N		N		CA-A1011/29	G
Australian National University	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2012: Equivalence of sun exposure and vitamin D supplementation in vitamin D insufficiency.	582,911.00	01/03/13	31/05/16	N		N		CA-A1213/43	G
Breast Cancer Network Australia	My Journey Kit	1,490,500.00	28/08/12	30/06/15	N		N		CA-A1112/51	G
Breast Cancer Network Australia	Hope and Hurdles Pack (transferred from NBOCC)	990,000.00	28/08/12	30/06/15	N		N		CA-A1112/51	G
Breast Cancer Network Australia	Funding Breast Cancer Network Australia	1,366,200.00	04/11/2011	30/06/2014	N		N		CA-A1112/06	G

(a)	(b)	(c)	(d)	(e)	(f)	(g)	(h)	(i)		
Contractor	Subject Matter	Amount of Consideration \$	Start Date	Anticipated End Date	Whether contract contains provisions requiring the parties to maintain confidentiality of any of its provisions (Y/N)	Reason(s)	Whether contract contains other requirements of confidentiality (Y/N)	Reason(s)	Agency Ref	Contract / Grant
Cancer Council QLD	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2010 - A multi-level investigation of inequalities in clinical and psychosocial outcomes for women after breast cancer	647,619.50	08/02/11	31/05/14	N		N		CA-A1011/14	G
Cooperative Trials Group for Neuro-Oncology (COGNO) through University of Sydney	Support for Cancer Clinical Trials - COGNO	1,379,859.00	25/06/13	31/08/16	N		N		CA-A1213/76	G
Curtin University of Technology	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2010: Meeting the education and support needs of women with breast cancer who are referred for radiotherapy: A multiple - baseline study	220,993.30	01/03/11	01/10/15	N		N		CA-A1011/41	G
Edith Cowan University	2011 Priority Driven Collaborative Cancer Research Scheme (PDCCRS) - Can exercise ameliorate treatment toxicity during the initial phase of testosterone suppression in prostate patients? Is this more effective than delayed rehabilitation and what is the time course and persistence of benefits?	163,634.55	02/02/12	28/05/15	N		N		CA-A1112/12	G

(a)	(b)	(c)	(d)	(e)	(f)	(g)	(h)	(i)		
Contractor	Subject Matter	Amount of Consideration \$	Start Date	Anticipated End Date	Whether contract contains provisions requiring the parties to maintain confidentiality of any of its provisions (Y/N)	Reason(s)	Whether contract contains other requirements of confidentiality (Y/N)	Reason(s)	Agency Ref	Contract / Grant
Finsbury Green	Printing of 'Guide for Women with Early Breast Cancer' and 'Guide for Women with Secondary Breast Cancer'.	203,894.00	04/06/13	30/06/13	N		N		CA-12-13/73 - D	C
Griffith University	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2010: ProsCan for Life: A Multimodal Supportive Care Intervention for Men with Prostate Cancer	329,006.70	24/01/11	30/04/14	N		N		CA-A1011/10	G
Ludwig Institute of Cancer Research	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2011: Discovery of colorectal cancer subtype associated tumour suppressor genes using next-generation sequencing and high throughput functional genomics	482,476.50	02/02/12	01/05/15	N		N		CA-A1112/11	G
Macquarie University	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2008: Evaluation of an online decision aid for women with breast cancer considering reconstructive surgery	103,803.34	30/01/09	30/04/14	N		N		CA-A0809/29	G

(a)	(b)	(c)	(d)	(e)	(f)	(g)	(h)	(i)		
Contractor	Subject Matter	Amount of Consideration \$	Start Date	Anticipated End Date	Whether contract contains provisions requiring the parties to maintain confidentiality of any of its provisions (Y/N)	Reason(s)	Whether contract contains other requirements of confidentiality (Y/N)	Reason(s)	Agency Ref	Contract / Grant
Melbourne Health	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2008: Resveratrol in the chemoprevention of colorectal neoplasia	633,325.00	18/08/11	03/05/14	N		N		CA-A0809/39	G
Menzies Research Institute	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2008: Integrative genomic approaches to understanding the genetics of prostate cancer	567,270.00	17/02/12	31/03/14	N		N		CA-A0809/11	G
Monash University	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2010: Determining the causes of observed variation in survival after diagnosis of prostate cancer	627,607.20	30/05/11	30/09/14	N		N		CA-A1011/52	G
Monash University	2012 Priority Driven Collaborative Cancer Research Scheme (PDCCRS): Defining Epigenetic Changes in Prostate Cancer Stroma. Appl ID 1044458	597,987.00	31/03/13	30/06/16	N		N		CA-A1213/60	G
National Breast Cancer Foundation	Establish a national cohort of Australian women recruited through BreastScreen Australia Services, for the purposes of developing a national database and resource, which can support a wide range of breast cancer studies to improve detection and treatment	2,749,823.47	30/06/09	30/09/14	N		N		CA-A0809/68	G

(a)	(b)	(c)	(d)	(e)	(f)	(g)	(h)	(i)		
Contractor	Subject Matter	Amount of Consideration \$	Start Date	Anticipated End Date	Whether contract contains provisions requiring the parties to maintain confidentiality of any of its provisions (Y/N)	Reason(s)	Whether contract contains other requirements of confidentiality (Y/N)	Reason(s)	Agency Ref	Contract / Grant
Prince Charles Hospital	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2008: Individualising treatment for mesothelioma	384,450.00	13/03/13	31/07/13	N		N		CA-A0809/48	G
Primary Care Collaborative Clinical trials Group (PC4TG) through University of Melbourne	Support for Cancer Clinical Trials - PC4TG	1,379,786.00	25/06/13	31/08/16	N		N		CA-A1213/71	G
Prostate Cancer Foundation Australia	Funding Agreement for PCFA - Supporting men with Prostate cancer	4,279,000.00	01/09/11	30/06/15	N		N		CA-A1112/04	G
Psycho-oncology Co-operative Research Group (PoCoG) through University of Sydney	Support for Cancer Clinical Trials - PoCoG	1,378,065.00	25/06/13	31/08/16	N		N		CA-A1213/75	G
Queensland Institute of Medical Research	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2010: Development of a model to classify mismatch repair gene sequence variants of uncertain clinical significance	660,000.00	16/09/13	31/05/15	N		N		CA-A1011/22	G
Queensland Institute of Medical Research	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2010: Identifying markers of risk and outcome in ovarian and breast cancer via efficient of DNA methylation in peripheral blood	191,213.00	15/02/11	31/05/14	N		N		CA-A1011/25	G

(a)	(b)	(c)	(d)	(e)	(f)	(g)	(h)	(i)		
Contractor	Subject Matter	Amount of Consideration \$	Start Date	Anticipated End Date	Whether contract contains provisions requiring the parties to maintain confidentiality of any of its provisions (Y/N)	Reason(s)	Whether contract contains other requirements of confidentiality (Y/N)	Reason(s)	Agency Ref	Contract / Grant
Queensland Institute of Medical Research	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2008: Towards new screening tests for oesophageal adenocarcinoma	512,325.00	01/01/09	31/03/14	N		N		CA-A0809/24	G
Queensland Institute of Medical Research	2008 Priority Driven Collaborative Cancer Research Scheme (PDCCRS): Improving Outcomes for Women with Endometrial Cancer: Follow-up, survival and quality of life: App ID 552468	656,466.80	21/01/09	31/03/14	N		N		CA-A0809/23	G
Queensland University of Technology	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2010: Skin cancer prevention & early detection for Generation Y	343,776.40	30/06/11	30/09/14	N		N		CA-A1011/55	G
Queensland University of Technology	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2012: Mirena ± Weight Loss to treat early Endometrial Cancer: (MAXWEL Trial). Appl ID 1044900	600,000.00	08/03/13	30/06/16	N		N		CA-A1213/66	G
State of Queensland through Queensland Health via The Princess Alexandra Hospital Metro South District	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2008: Phase II Efficacy Study of Chemo-Radiotherapy in PET Staged II-III Merkel Cell Carcinoma of the Skin	101,750.00	11/05/12	30/04/15	N		N		CA-A0809/06	G

(a)	(b)	(c)	(d)	(e)	(f)	(g)	(h)	(i)		
Contractor	Subject Matter	Amount of Consideration \$	Start Date	Anticipated End Date	Whether contract contains provisions requiring the parties to maintain confidentiality of any of its provisions (Y/N)	Reason(s)	Whether contract contains other requirements of confidentiality (Y/N)	Reason(s)	Agency Ref	Contract / Grant
State of Queensland through Queensland Health via The Princess Alexandra Hospital Metro South District	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2011: A randomised Phase III trial of High Dose Palliative Radiotherapy (HDPRT) versus concurrent Chemotherapy and HDPRT (C-HDPRT) in patients with Good performance Status. Locally Advanced/Small Volume Metastatic Non-small Cell Lung Cancer	327,214.80	21/02/12	30/07/15	N		N		CA-A1112/20	G
The Trustee of the National Breast Cancer Foundation	Developing a National Database and Resource which can Support a wide range of Breast Cancer Studies to Improve Detection and Treatment	\$2,749,823.47	30/06/2009	30/06/2014	N		N		CA-A0910/94	G
Trans Tasman Radiation Oncology Group Limited (TROG)	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2009: A randomised comparison of anastrozole commenced before and continued during adjuvant radiotherapy for breast cancer versus anastrozole and subsequent anti-oestrogen therapy delayed until after radiotherapy	660,000.00	25/06/10	30/09/14	N		N		CA-A0910/118	G
Trans Tasman Radiation Oncology Group Limited (TROG)	Support for Cancer Clinical Trials - TROG	1,518,000.00	25/06/13	31/08/16	N		N		CA-A1213/72	G

(a)	(b)	(c)	(d)	(e)	(f)	(g)	(h)	(i)		
Contractor	Subject Matter	Amount of Consideration \$	Start Date	Anticipated End Date	Whether contract contains provisions requiring the parties to maintain confidentiality of any of its provisions (Y/N)	Reason(s)	Whether contract contains other requirements of confidentiality (Y/N)	Reason(s)	Agency Ref	Contract / Grant
University of Adelaide	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2010: The role of CD123 in MDSA and AML	316,276.40	28/02/11	13/06/14	N		N		CA-A1011/33	G
University of Adelaide	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2010: A novel approach to predict metastatic potential of prostate cancer at diagnosis	650,905.20	01/03/2011□	30/06/14	N		N		CA-A1011/42	G
University of Adelaide	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2011: Androgen receptor action in the prostate cancer microenvironment	316,571.20	20/03/12	31/08/2015□	N		N		CA-A1112/33	G
University of Adelaide	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2011: Is elevated N-cadherin expression a poor prognostic indicator in multiple myeloma patients	290,766.30	20/03/2012□	17/06/16	N		N		CA-A1112/36	G

(a)	(b)	(c)	(d)	(e)	(f)	(g)	(h)	(i)		
Contractor	Subject Matter	Amount of Consideration \$	Start Date	Anticipated End Date	Whether contract contains provisions requiring the parties to maintain confidentiality of any of its provisions (Y/N)	Reason(s)	Whether contract contains other requirements of confidentiality (Y/N)	Reason(s)	Agency Ref	Contract / Grant
University of Adelaide	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2012: A pharmacodynamic study of the heat shock protein 90 (Hsp90) inhibitor, AUY922, in high-risk, localised prostate cancer.	360,977.00	01/05/13	31/07/16	N		N		CA-A1213/28	G
University of Adelaide	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2012: Mechanism and targeting of castration-resistant prostate cancer.	270,569.00	11/02/2013	30/06/16	N		N		CA-A1213/29	G
University of Adelaide	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2012: Targeting the androgen receptor in triple negative breast cancer. Appl ID 1043497.	196,474.70	11/02/13	30/06/16	N		N		CA-A1213/30	G

(a)	(b)	(c)	(d)	(e)	(f)	(g)	(h)	(i)		
Contractor	Subject Matter	Amount of Consideration \$	Start Date	Anticipated End Date	Whether contract contains provisions requiring the parties to maintain confidentiality of any of its provisions (Y/N)	Reason(s)	Whether contract contains other requirements of confidentiality (Y/N)	Reason(s)	Agency Ref	Contract / Grant
University of Melbourne	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2008: A randomised trial of stereotactic vs conventional radiotherapy for inoperable early stage non-small cell lung cancer	286,000.00	05/03/12	31/03/14	N		N		CA-A0809/45	G
University of Melbourne	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2009: Novel MicroRNA regulators in the Breast Cancer EMT	281,620.90	01/03/10	31/03/14	N		N		CA-A0910/50	G
University of Melbourne	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2009: A randomised controlled trial evaluating a nurse-led survivorship care package (SurvivorCare) for bowel cancer survivors	206,250.00	21/05/12	31/10/14	N		N		CA-A0910/86	G
University of Melbourne	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2010: Phase III randomised trial of post mastectomy chest wall irradiation in intermediate risk operable breast cancer	561,000.00	09/02/11	31/08/14	N		N		CA-A1011/15	G

(a)	(b)	(c)	(d)	(e)	(f)	(g)	(h)	(i)		
Contractor	Subject Matter	Amount of Consideration \$	Start Date	Anticipated End Date	Whether contract contains provisions requiring the parties to maintain confidentiality of any of its provisions (Y/N)	Reason(s)	Whether contract contains other requirements of confidentiality (Y/N)	Reason(s)	Agency Ref	Contract / Grant
University of Melbourne	2010 Priority Driven Collaborative Cancer Research Scheme (PDCCRS): Genetic and environmental factors in invasive cervical cancer: a twin study	429,458.70	09/02/11	14/05/14	N		N		CA-A1011/16	G
University of Melbourne	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2010: Fulfilling the vision of youth-friendly cancer care: How well are we meeting the psychosocial needs of AYA patients?	164,776.70	09/02/11	27/05/14	N		N		CA-A1011/17	G
University of Melbourne	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2010: Identifying therapeutic targets by profiling DNA repair in lung cancer	552,776.40	09/02/11	31/05/14	N		N		CA-A1011/18	G
University of Melbourne	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2010: Personalised breast cancer risk prediction in BRCA mutation carriers	152,780.10	09/02/11	30/06/14	N		N		CA-A1011/19	G
University of Melbourne	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2010: Identification of Men with a genetic predisposition to Prostate Cancer: targeted screening in BRCA1/2 mutation carriers and controls - The Impact study	465,329.70	09/02/11	31/05/14	N		N		CA-A1011/20	G

(a)	(b)	(c)	(d)	(e)	(f)	(g)	(h)	(i)		
Contractor	Subject Matter	Amount of Consideration \$	Start Date	Anticipated End Date	Whether contract contains provisions requiring the parties to maintain confidentiality of any of its provisions (Y/N)	Reason(s)	Whether contract contains other requirements of confidentiality (Y/N)	Reason(s)	Agency Ref	Contract / Grant
University of Melbourne	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2010: Sequencing the ovarian cancer genome: molecular determinants of tumour growth & treatment failure	660,000.00	30/06/11	30/09/14	N		N		CA-A1011/54	G
University of Melbourne	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2011: Targeting dormancy in metastatic breast cancer	148,179.90	23/02/12	28/05/15	N		N		CA-A1112/15	G
University of Melbourne	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2011: Defining the hereditary contribution to ovarian cancer: The role of mismatch repair genes	614,090.40	23/02/12	28/05/15	N		N		CA-A1112/16	G
University of Melbourne	2011 Priority Driven Collaborative Cancer Research Scheme (PDCCRS): Determining Predictors of Sensitivity to Chk Inhibitors in Metastatic Melanoma	651,585.00	14/03/12	28/05/15	N		N		CA-A1112/31	G
University of Melbourne	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2012: Solving Unknown Primary cancer - SUPER. Appl ID 1048193.	599,381.00	01/06/13	31/08/16	N		N		CA-A1213/21	G

(a)	(b)	(c)	(d)	(e)	(f)	(g)	(h)	(i)		
Contractor	Subject Matter	Amount of Consideration \$	Start Date	Anticipated End Date	Whether contract contains provisions requiring the parties to maintain confidentiality of any of its provisions (Y/N)	Reason(s)	Whether contract contains other requirements of confidentiality (Y/N)	Reason(s)	Agency Ref	Contract / Grant
University of Melbourne	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2012: High Risk genes for Lobular Breast Cancer. Appl ID 1047347.	100,000.00	01/03/13	31/05/16	N		N		CA-A1213/24	G
University of New South Wales	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2008: The use and impact of cancer medicines in real world clinical practice: Evaluation in a cohort of elderly Australians	459,525.00	03/05/11	31/03/14	N		N		CA-A0809/26	G
University of New South Wales	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2011: Mechanisms underpinning how brain cancer cells respond to drugs	534,793.00	20/03/12	30/06/15	N		N		CA-A1112/28	G
University of New South Wales	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2011: 'ReCaPTure LiFe': A phase 11 randomised trial of a psychological intervention to support adolescent and young adult cancer survivors	148,811.85	17/02/12	13/06/14	N		N		CA-A1112/29	G
University of New South Wales	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2008: Development of an optimised intervention for post-cancer fatigue	474,650.00	15/06/09	30/09/14	N		N		CA-A0809/64	G

(a)	(b)	(c)	(d)	(e)	(f)	(g)	(h)	(i)		
Contractor	Subject Matter	Amount of Consideration \$	Start Date	Anticipated End Date	Whether contract contains provisions requiring the parties to maintain confidentiality of any of its provisions (Y/N)	Reason(s)	Whether contract contains other requirements of confidentiality (Y/N)	Reason(s)	Agency Ref	Contract / Grant
University of Queensland	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2010: Auto fluorescence imaging for early detection and surgical margin delineation of oral cancers and pre-cancers	558,131.20	28/02/11	02/08/14	N		N		CA-A1011/32	G
University of Sydney	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2012: A Phase II study to evaluate the safety and potential benefit of intraperitoneal (IP) bevacizumab to control symptomatic malignant ascites in patients with chemotherapy resistant ovarian cancers: REZOLVE (ANZGOG-1101).	277,958.00	28/06/13	29/09/13	N		N		CA-A1213/84	G
University of Sydney	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2008: Preferences for adjuvant chemotherapy in early non-small-cell lung cancer: what makes it worthwhile?	316,167.50	31/01/09	31/03/14	N		N		CA-A0809/33	G

(a)	(b)	(c)	(d)	(e)	(f)	(g)	(h)	(i)		
Contractor	Subject Matter	Amount of Consideration \$	Start Date	Anticipated End Date	Whether contract contains provisions requiring the parties to maintain confidentiality of any of its provisions (Y/N)	Reason(s)	Whether contract contains other requirements of confidentiality (Y/N)	Reason(s)	Agency Ref	Contract / Grant
University of Sydney	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2009: Randomised trial of consumer-led familial cancer risk tool & GP triage on risk-appropriate colorectal cancer screening	611,875.00	26/02/10	31/03/14	N		N		CA-A0910/70	G
University of Sydney	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2009: Timing of surgery and adjuvant chemotherapy for hepatic metastases from colorectal cancer	660,000.00	21/05/12	31/10/14	N		N		CA-A0910/73	G
University of Sydney	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2010: Whole Brain Radiotherapy following local treatment of intracranial metastases of melanoma - a randomised phase III trial	650,111.00	01/03/11	31/05/14	N		N		CA-A1011/37	G
University of Sydney	2010 Priority Driven Collaborative Cancer Research Scheme (PDCCRS): START Phase III Study of Active Surveillance Therapy Against Radical Treatment in Patients Diagnosed with Favourable Risk Prostate Cancer	329,320.20	01/03/11	31/05/14	N		N		CA-A1011/40	G

(a)	(b)	(c)	(d)	(e)	(f)	(g)	(h)	(i)		
Contractor	Subject Matter	Amount of Consideration \$	Start Date	Anticipated End Date	Whether contract contains provisions requiring the parties to maintain confidentiality of any of its provisions (Y/N)	Reason(s)	Whether contract contains other requirements of confidentiality (Y/N)	Reason(s)	Agency Ref	Contract / Grant
University of Sydney	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2010: NITRO - A randomised, phase 3 trial of adding nitroglycerin to first line chemotherapy for advanced non - small cell lung cancer	656,421.70	01/03/11	31/05/14	N		N		CA-A1011/45	G
University of Sydney	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2011: The role of adjuvant chemotherapy in high-risk endometrial cancer	330,965.80	09/01/12	30/05/15	N		N		CA-A1112/08	G
University of Sydney	2011 Priority Driven Collaborative Cancer Research Scheme (PDCCRS): Phase III trial of Concurrent and Adjuvant Temozolomide chemotherapy in non-1p/19q non deleted anaplastic glioma. The CATNON Intergroup Trial: App ID 1026842	217,896.25	09/01/12	30/04/15	N		N		CA-A1112/09	G
University of Sydney	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2011: Evaluation of web-based tool for estimating and explaining prognosis in advanced cancer	139,933.75	09/01/12	30/04/15	N		N		CA-A1112/13	G

(a)	(b)	(c)	(d)	(e)	(f)	(g)	(h)	(i)		
Contractor	Subject Matter	Amount of Consideration \$	Start Date	Anticipated End Date	Whether contract contains provisions requiring the parties to maintain confidentiality of any of its provisions (Y/N)	Reason(s)	Whether contract contains other requirements of confidentiality (Y/N)	Reason(s)	Agency Ref	Contract / Grant
University of Sydney	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2011: Evaluation of a psychological and educational intervention for fear of cancer recurrence; A cluster randomised controlled trial	182,124.07	09/01/12	28/05/15	N		N		CA-A1112/14	G
University of Sydney	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2012: PETACC-6: Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and oxaliplatin vs. capecitabine alone in locally advanced rectal cancer.	123,331.00	04/03/13	03/06/16	N		N		CA-A1213/45	G
University of Sydney	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2012: The Use and Impact of High Cost Targeted Cancer Medicines: Theory and Reality.	133,002.00	04/03/13	03/06/16	N		N		CA-A1213/55	G
University of Sydney	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2012: Accelerating First-Line Chemotherapy to Improve Cure Rates for Advanced Germ Cell Tumours: An Australian-Led, International Randomised Trial. Appl ID 1041733	252,583.48	01/06/13	31/08/16	N		N		CA-A1213/56	G

(a)	(b)	(c)	(d)	(e)	(f)	(g)	(h)	(i)		
Contractor	Subject Matter	Amount of Consideration \$	Start Date	Anticipated End Date	Whether contract contains provisions requiring the parties to maintain confidentiality of any of its provisions (Y/N)	Reason(s)	Whether contract contains other requirements of confidentiality (Y/N)	Reason(s)	Agency Ref	Contract / Grant
University of Sydney	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2012: The cost-effectiveness of adjuvant whole brain radiotherapy for melanoma brain metastases: a trial-based and modelled economic evaluation. Appl ID 1046923	184,475.00	04/03/13	03/06/16	N		N		CA-A1213/57	G
University of Sydney	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2012: Adding mitomycin C to intravesical BCG for high-risk, non-muscle-invasive bladder cancer: a randomised phase 3 trial.	457,143.17	01/06/13	31/08/16	N		N		CA-A1213/58	G
University of Sydney	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2011: Ginkgo biloba preserves cognitive function in women treated with adjuvant chemotherapy for early breast cancer: a double-blind, placebo-controlled, randomised phase III trial	220,000.00	17/02/12	16/11/16	N		N		CA-A1112/24	G
University of Sydney	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2011: The use of RNAi to identify new therapeutic targets for malignant mesothelioma	407,523.10	21/02/12	16/02/15	N		N		CA-A1112/26	G

(a)	(b)	(c)	(d)	(e)	(f)	(g)	(h)	(i)		
Contractor	Subject Matter	Amount of Consideration \$	Start Date	Anticipated End Date	Whether contract contains provisions requiring the parties to maintain confidentiality of any of its provisions (Y/N)	Reason(s)	Whether contract contains other requirements of confidentiality (Y/N)	Reason(s)	Agency Ref	Contract / Grant
University of Sydney	2008 Priority Driven Collaborative Cancer Research Scheme (PDCCRS): Randomised phase III study of preop-chemoradiotherapy versus preop-chemotherapy for resectable gastric cancer: App ID 570996	595,301.66	31/01/09	31/04/2015	N		N		CA-A0809/36	G
University of Western Australia	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2010: Endocrine therapies for early breast cancer: targets the National Health Priority Area of Cancer Control, specifically focussing on breast cancer treatment in Australian women.	171,048.90	07/02/11	31/07/14	N		N		CA-A1011/13	G
University of Wollongong	Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2011: Quantifying the impact of imaging choice for breast cancer radiotherapy	143,585.20	21/02/12	01/06/15	N		N		CA-A1112/19	G